Accumulation of segmental alterations determines progression in neuroblastoma.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Oncology

• Publication date

  2010-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1200/JCO.2009.26.7955PMID 20516441
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overall genomic pattern is a predictor of outcome in neuroblastoma.

  2009cited by this paper
• Chromosomal Instability and Copy Number Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma

  2009cited by this paper
• Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.

  2008cited by this paper
• Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia

  2008cited by this paper
• Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97.

  2008cited by this paper
• New players in the BRCA1-mediated DNA damage responsive pathway.

  2008cited by this paper
• Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature

  2008cited by this paper
• Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.

  2008cited by this paper
• High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays.

  2007cited by this paper
• Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification

  2007cited by this paper
• ArrayCGH‐based classification of neuroblastoma into genomic subgroups

  2007cited by this paper
• Genome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays

  2007cited by this paper
• Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression

  2007cited by this paper
• High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.

  2006cited by this paper
• VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles

  2006cited by this paper
• Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.

  2006cited by this paper
• Comparative genomic hybridization reveals genetic progression of oral squamous cell carcinoma from dysplasia via two different tumourigenic pathways

  2006cited by this paper
• Analysis of chromosome breakpoints in neuroblastoma at sub‐kilobase resolution using fine‐tiling oligonucleotide array CGH

  2005cited by this paper
• Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain

  2005cited by this paper
• Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.

  2005cited by this paper
• Preferential Occurrence of Chromosome Breakpoints within Early Replicating Regions in Neuroblastoma

  2005cited by this paper
• Chromosome 1p and 11q deletions and outcome in neuroblastoma.

  2005cited by this paper
• Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.

  2005cited by this paper
• Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.

  2005cited by this paper
• Analysis of array CGH data: from signal ratio to gain and loss of DNA regions

  2004cited by this paper
• Gene expression profiling of 1p35–36 genes in neuroblastoma

  2004cited by this paper
• Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors.

  2003cited by this paper
• Neuroblastoma: biological insights into a clinical enigma

  2003cited by this paper
• Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma.

  2003cited by this paper
• Screening of infants and mortality due to neuroblastoma.

  2002cited by this paper
• Neuroblastoma screening at one year of age.

  2002cited by this paper
• Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors.

  2001cited by this paper
• Prognostic significance of DNA di-tetraploidy in neuroblastoma.

  2001cited by this paper
• Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification

  2001cited by this paper
• Genome maintenance mechanisms for preventing cancer

  2001cited by this paper
• Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?

  2001cited by this paper
• Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.

  1999cited by this paper
• Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).

  1997cited by this paper
• Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.

  1996cited by this paper
• Clinical relevance of loss of heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single‐institution study

  1996cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.

  1993cited by this paper
• Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

  1985cited by this paper
• Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma.

  1984cited by this paper

• Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk

  2026cites this paper
• Pathology of peripheral neuroblastic tumors

  2026cites this paper
• Neuroblastoma in Infants: Long‐Term Survival From INES Protocols A SIOPEN Study

  2025cites this paper
• Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

  2024cites this paper
• A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations

  2024cites this paper
• USP44 Overexpression Drives a MYC-Like Gene Expression Program in Neuroblastoma through Epigenetic Reprogramming

  2024cites this paper
• Overexpression of H2AFX gene in neuroblastoma is associated with worse prognosis

  2024cites this paper
• Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review

  2024cites this paper
• DNA Repair and Replicative Stress Addiction in Neuroblastoma

  2024cites this paper
• Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status

  2024cites this paper
• Segmental chromosome aberrations as a prognostic factor of neuroblastoma: a meta-analysis and systematic review

  2024cites this paper
• Children's Oncology Group's 2023 blueprint for research: Neuroblastoma

  2023cites this paper
• Targeting neuroblastoma by small-molecule inhibitors of human ALYREF protein: mechanistic insights using molecular dynamics simulations

  2023cites this paper
• Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA

  2023cites this paper
• Comparative Clinicopathological and Genomic Analysis of Hepatocellular Neoplasm, NOS and Hepatoblastoma.

  2023cites this paper
• Neuroblastoma Patients’ Outcome and Chromosomal Instability

  2023cites this paper
• Technical Implications of the Chicken Embryo Chorioallantoic Membrane Assay to Elucidate Neuroblastoma Biology

  2023cites this paper
• Stage 4N neuroblastoma before and during the era of anti‐GD2 immunotherapy

  2023cites this paper
• Development and validation of a 21-gene prognostic signature in neuroblastoma

  2023cites this paper
• Infantile Stage M Neuroblastoma With 11q Deletion, Mimicking Stage MS

  2022cites this paper
• Targeting the DNA damage response in pediatric malignancies

  2022cites this paper
• Extracellular Vesicles: A New Source of Biomarkers in Pediatric Solid Tumors? A Systematic Review

  2022cites this paper
• Chromosome instability in neuroblastoma: A pathway to aggressive disease

  2022cites this paper
• Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma

  2022cites this paper
• Super-enhancer-associated INSM2 regulates lipid metabolism by modulating mTOR signaling pathway in neuroblastoma

  2022cites this paper
• Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma

  2022cites this paper
• The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma

  2021cites this paper
• Molecular Genetics in Neuroblastoma Prognosis

  2021cites this paper
• Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94

  2021cites this paper
• Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

  2021cites this paper
• High Grade of Amplification of Six Regions on Chromosome 2p in a Neuroblastoma Patient with Very Poor Outcome: The Putative New Oncogene TSSC1

  2021cites this paper
• Constrained energy variation for change point detection

  2021cites this paper
• From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma

  2021cites this paper
• Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children’s Cancer Group Neuroblastoma Committee (JCCG-JNBSG)

  2021cites this paper
• Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma

  2021cites this paper
• Association of high-risk neuroblastoma classification based on expression profiles with differentiation and metabolism

  2021cites this paper
• Emerging therapeutic targets for neuroblastoma

  2020cites this paper
• gfpop: An R Package for Univariate Graph-Constrained Change-Point Detection

  2020cites this paper
• Optimization of percutaneous biopsy for diagnosis and pretreatment risk assessment of neuroblastoma

  2020cites this paper
• Clinical Significance of Segmental Chromosomal Aberrations in Patients with Neuroblastoma: First Report in Korean Population

  2020cites this paper
• Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.

  2020cites this paper
• Labeled optimal partitioning

  2020cites this paper
• Circulating tumor DNA in neuroblastoma

  2020cites this paper
• Distribution of segmental chromosomal alterations in neuroblastoma

  2020cites this paper
• Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma

  2020cites this paper
• Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes

  2020cites this paper
• Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.

  2020cites this paper
• SH-SY5Y-derived Neurons: A Neuronal Model System for Investigating TAU Sorting Mechanisms and Neuronal Subtype-specific TAU Vulnerability

  2020cites this paper
• Neuroblastoma

  2020cites this paper
• SH-SY5Y-derived neurons: a human neuronal model system for investigating TAU sorting and neuronal subtype-specific TAU vulnerability

  2020cites this paper
• ijms-648549 2nd Revision by Ugo Rovigatti

  2020cites this paper
• Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles

  2020cites this paper
• The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL).

  2020cites this paper
• Loss of whole chromosome X predicts prognosis of neuroblastoma patients with numerical genomic profile

  2019cites this paper
• Neuroblastoma Pathogenesis

  2019cites this paper
• High-Risk Neuroblastoma and Current Protocols

  2019cites this paper
• Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma.

  2019cites this paper
• Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients

  2019cites this paper
• Opportunities and challenges of circulating biomarkers in neuroblastoma

  2019cites this paper
• Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages

  2019cites this paper
• Neuroblastoma in Adolescents and Children Older than 10 Years: Unusual Clinicopathologic and Biologic Features

  2019cites this paper
• Novel Inflammatory Mediators in Neuroblastoma Tumorigenesis

  2019cites this paper
• Novel Therapeutic Targets in Neuroblastoma

  2019cites this paper
• Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment

  2019cites this paper
• Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients

  2018cites this paper
• Cancer evolution, mutations, and clonal selection in relapse neuroblastoma

  2018cites this paper
• Clinical Presentation, Evaluation, and Management of Neuroblastoma

  2018cites this paper
• 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients.

  2018cites this paper
• 65 YEARS OF THE DOUBLE HELIX: Classification of endocrine tumors in the age of integrated genomics.

  2018cites this paper
• Neuroblastoma

  2018cites this paper
• Introduction to Pediatric Cancer Immunotherapy

  2018cites this paper
• Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy

  2018cites this paper
• Cancer evolution, mutations, and clonal selection in relapse neuroblastoma

  2018cites this paper
• Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

  2017cites this paper
• Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation

  2017cites this paper
• Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone

  2017cites this paper
• Analysis of the antiproliferative effects of the Schwann cell on neuroblastoma cells

  2017cites this paper
• Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979–2015

  2017cites this paper
• Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis

  2017cites this paper
• Transcription instability in high‐risk neuroblastoma is associated with a global perturbation of chromatin domains

  2017cites this paper
• Growth, progression and chromosome instability of Neuroblastoma: a new scenario of tumorigenesis?

  2017cites this paper
• The Origin of Neuroblastoma The Origin of Neuroblastoma

  2017cites this paper
• 11q deletion in neuroblastoma: a review of biological and clinical implications

  2017cites this paper
• Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome

  2017cites this paper
• A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis.

  2017cites this paper
• Characterization of Chromosomal Aberrationsin Neuroblastoma Formalin-Fixed Paraffin-Embedded Specimens with StandardArrayCGH Procedure - Preliminary Experience

  2017cites this paper
• The Origin of Neuroblastoma

  2017cites this paper
• Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival

  2017cites this paper
• Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice

  2016cites this paper
• Neuroblastoma presenting with symptoms of epidural compression at birth: a case report

  2016cites this paper
• Genomic Analysis of Bone Marrow-Derived Disseminated Neuroblastoma Cells

  2016influential citation
• Genetic discoveries and treatment advances in neuroblastoma

  2016cites this paper
• Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations

  2016influential citation
• Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin‐Fixed Paraffin‐Embedded Tissue Samples and Are Associated With Recurrence

  2016cites this paper
• Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse

  2016cites this paper
• Transcript signatures that predict outcome and identify targetable pathways in MYCN‐amplified neuroblastoma

  2016cites this paper
• Minimal residual disease monitoring in neuroblastoma

  2016cites this paper
• Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.

  2016cites this paper
• Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma

  2016cites this paper
• Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.

  2016cites this paper